The stock of Aeterna Zentaris Incorporated (NASDAQ:AEZS) registered a decrease of 9.63% in short interest. AEZS’s total short interest was 694,500 shares in September as published by FINRA. Its down 9.63% from 768,500 shares, reported previously. With 65,100 shares average volume, it will take short sellers 11 days to cover their AEZS’s short positions. The short interest to Aeterna Zentaris Incorporated’s float is 7.02%. About 77,460 shares traded hands. AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) has risen 20.00% since February 8, 2016 and is uptrending. It has outperformed by 3.51% the S&P500.
Aeterna Zentaris Inc. is a specialty biopharmaceutical firm engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The company has a market cap of $33.55 million. The Firm operates through the biopharmaceutical segment. It currently has negative earnings. The Firm is engaged in drug development activities and in the promotion of products for others.
Out of 3 analysts covering Aeterna Zentaris Inc. (NASDAQ:AEZS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $12.0 is the highest target while $11 is the lowest. The $11.50 average target is 233.33% above today’s ($3.45) stock price. Aeterna Zentaris Inc. has been the topic of 4 analyst reports since November 9, 2015 according to StockzIntelligence Inc. H.C. Wainwright maintained the stock on December 2 with “Buy” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.